Top

Journal of Radiation Oncology

Published in:

01-09-2019 | Brachytherapy | Original Research

Definitive chemoradiation followed by stereotactic body radiotherapy boost for inoperable endometrial cancer

Authors: Shraddha M. Dalwadi, Constantine Mantz, Bui Tung, Nabila Waheed, Danny Tran, Mark Bonnen, Michelle Ludwig

Published in: Journal of Radiation Oncology | Issue 3/2019

Abstract

Objectives

For inoperable endometrial cancer (ECA) patients, definitive chemoradiation with stereotactic body radiotherapy (SBRT) boost may be an option. SBRT schedules and dose distributions approximate brachytherapy boost (BB) radiobiologic dosing, while eliminating the need for applicator placement and thus anesthesia. We report toxicity, disease control, and quality-of-life outcomes of a multi-institutional series of SBRT for ECA.

Methods

Twenty-three patients met the following eligibility criteria: (1) primary ECA, (2) contraindication or refusal of BB, and (3) need for definitive radiation (RT). Prior to SBRT, patients received pelvic RT +/− nodal boost concurrent with cisplatin. SBRT dose of 25.0–35.0 Gy was prescribed to a high-risk clinical target volume (HR-CTV) in 4–5 fractions. Assessments included (1) post-treatment disease surveillance, (2) toxicity using the U.S. National Cancer Institute’s CTCAE scales, and (3) quality-of-life using FACT-G.

Results

Median follow-up was 31 months. BB was infeasible due to medical comorbidities, patient refusal, and technical contraindications (73.9%, 21.7%, and 4.3%, respectively). Most patients were FIGO stage I (60.8%). Mean cumulative dose to high-risk clinical target volume (HR-CTV) was 88.94 Gy (range 75.50–93.83 Gy). Mean SBRT dose to 95% of the planning target volume (PTV) was 32.55 Gy (range 25.00–35.77 Gy), and mean PTV receiving 100% of the dose was 95.29% (range 91.48–99.01%). No patients had grade 2+ long-term gastrointestinal or genitourinary toxicity. Locoregional and distant control was 91.6% at 1 year and 85.4% at 2 year. Only one patient died due to ECA at 6 months. Overall survival was 95.0% at 1 year, 74.0% at 2 year, and 59.2% at 5 year. Patient-reported physical and emotional well-being worsened but improved after the acute phase of treatment. Functional and social/family well-being worsened after 1 month.

Conclusion

Definitive chemoradiation with SBRT boost is safe and effective alternative when BB is not possible.

Cancer Stat Facts: uterine cancer. Uterine Cancer - Cancer Stat Facts, SEER. seer.cancer.gov/statfacts/html/corp.html

Koh W-J et al (2018) Uterine neoplasms, version 1.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 16(2):170–199CrossRef

Rosato V, Zucchetto A, Bosetti C, Dal Maso L, Montella M, Pelucchi C, Negri E, Franceschi S, la Vecchia C (2010) Metabolic syndrome and endometrial cancer risk. Ann Oncol 22(4):884–889CrossRef

Kim JJ, Kurita T, Bulun SE (2013) Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev 34(1):130–162CrossRef

MacMahon B (1974) Risk factors for endometrial cancer. Gynecol Oncol 2(2):122–129CrossRef

Fishman DA et al (1996) Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma of the endometrium. Gynecol Oncol 61(2):189–196CrossRef

Varia M et al (1987) Primary radiation therapy for medically inoperable patients with endometrial carcinoma-stages I–II. Int J Radiat Oncol Biol Phys 13(1):11–15CrossRef

Kucera H et al (1998) Treatment of endometrial carcinoma with high-dose-rate brachytherapy alone in medically inoperable stage I patients. Acta Obstet Gynecol Scand 77(10):1008–1012CrossRef

Nag S et al (2000) The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the endometrium. Int J Radiat Oncol Biol Phys 48(3):779–790CrossRef

10.

Potters L et al (2010) American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 76(2):326–332CrossRef

11.

Jones R et al (2014) Dosimetric feasibility of stereotactic body radiation therapy as an alternative to brachytherapy for definitive treatment of medically inoperable early stage endometrial cancer. Radiat Oncol 9(1):164CrossRef

12.

Kemmerer E et al (2013) Use of image-guided stereotactic body radiation therapy in lieu of intracavitary brachytherapy for the treatment of inoperable endometrial neoplasia. Int J Radiat Oncol Biol Phys 85(1):129–135CrossRef

13.

Demiral S, Beyzadeoglu M, Uysal B, Oysul K, Kahya YE, Sager O, Dincoglan F, Gamsiz H, Dirican B, Surenkok S (2013) Evaluation of stereotactic body radiotherapy (SBRT) boost in the management of endometrial cancer. Neoplasma 60(3):322–327CrossRef

14.

Higginson DS et al (2011) Stereotactic body radiotherapy (SBRT): technological innovation and application in gynecologic oncology. Gynecol Oncol 120(3):404–412CrossRef

15.

Cengiz M et al (2012) Comparison of intracavitary brachytherapy and stereotactic body radiotherapy dose distribution for cervical cancer. Brachytherapy 11(2):125–129CrossRef

16.

Spratt DE et al (2013) A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer. Brachytherapy 12(5):428–433CrossRef

17.

Jabbari S et al (2012) Stereotactic body radiotherapy as monotherapy or post–external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys 82(1):228–234CrossRef

18.

Katz A, Kang J (2014) Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study. Radiat Oncol 9(1):1CrossRef

19.

Nag S, Gupta N (2000) A simple method of obtaining equivalent doses for use in HDR brachytherapy. Int J Radiat Oncol Biol Phys 46(2):507–513CrossRef

20.

Haas JA, Witten MR, Clancey O, Episcopia K, Accordino D, Chalas E (2012) CyberKnife boost for patients with cervical cancer unable to undergo brachytherapy. Front Oncol 2, article 25

21.

Molla M, Escude L, Nouet P et al (2005) Fractionated stereotactic radiotherapy boost for gynecologic tumors: an alternative to brachytherapy? Int J Radiat Oncol Biol Phys 62(1):118–124CrossRef

22.

Guckenberger M, Bachmann J, Wulf J, Mueller G, Krieger T, Baier K, Richter A, Wilbert J, Flentje M (2010) Stereotactic body radiotherapy for local boost irradiation in unfavourable locally recurrent gynaecological cancer. Radiother Oncol 94(1):53–59CrossRef

23.

Park HC, Shimizu S, Yonesaka A, Tsuchiya K, Ebina Y, Taguchi H, Katoh N, Kinoshita R, Ishikawa M, Sakuragi N, Shirato H (2010) High dose three-dimensional conformal boost using the real-time tumor tracking radiotherapy system in cervical cancer patients unable to receive intracavitary brachytherapy. Yonsei Med J 51:93–99CrossRef

24.

Matsuura K, Tanimoto H, Fujita K, Hashimoto Y, Murakami Y, Kenjo M et al (2007) Early clinical outcomes of 3D-conformal radiotherapy using accelerated hyperfractionation without intracavitary brachytherapy for cervical cancer. Gynecol Oncol 104:11–14CrossRef

25.

Georg D et al (2008) Image-guided radiotherapy for cervix cancer: high-tech external beam therapy versus high-tech brachytherapy. Int J Radiat Oncol Biol Phys 71(4):1272–1278CrossRef

26.

Barraclough LH et al (2008) External beam boost for cancer of the cervix uteri when intracavitary therapy cannot be performed. Int J Radiat Oncol Biol Phys 71(3):772–778CrossRef

27.

Berggren D et al (1987) Postoperative confusion after anesthesia in elderly patients with femoral neck fractures. Anesth Analg 66(6):497–504CrossRef

28.

Grosso G et al (2012) Major postoperative complications and survival for colon cancer elderly patients. BMC Surg 12(1):S20CrossRef

29.

Kirchheiner K et al (2014) Posttraumatic stress disorder after high-dose-rate brachytherapy for cervical cancer with 2 fractions in 1 application under spinal/epidural anesthesia: incidence and risk factors. Int J Radiat Oncol Biol Phys 89(2):260–267CrossRef

30.

Kirchheiner K et al (2015) Health related quality of life and patient reported symptoms before and during definitive radio (chemo) therapy using image-guided adaptive brachytherapy for locally advanced cervical cancer and early recovery—a mono-institutional prospective study. Gynecol Oncol 136(3):415–423CrossRef

Title: Definitive chemoradiation followed by stereotactic body radiotherapy boost for inoperable endometrial cancer
Authors: Shraddha M. Dalwadi
Constantine Mantz
Bui Tung
Nabila Waheed
Danny Tran
Mark Bonnen
Michelle Ludwig
Publication date: 01-09-2019
Publisher: Springer Berlin Heidelberg
Keywords: Brachytherapy
Radiotherapy
Endometrial Cancer
Endometrial Cancer
Published in: Journal of Radiation Oncology / Issue 3/2019
Print ISSN: 1948-7894
Electronic ISSN: 1948-7908
DOI: https://doi.org/10.1007/s13566-019-00403-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2019

Thoracic radiotherapy for extensive-stage small-cell lung cancer: what is the optimal dose and timing?

Long-term clinical outcomes of 538 prostate carcinoma patients treated with combination high-dose-rate brachytherapy and external beam radiotherapy

Patterns of utilization and comparative efficacy of altered fractionation and concurrent chemoradiation for treatment for T2N0M0 glottic carcinoma

Therapeutic value of postmastectomy radiation therapy for T1–2 breast cancer with 1–3 positive lymph nodes

Dosimetric evaluation of the dose calculation accuracy of different algorithms for two different treatment techniques during whole breast irradiation

Impact of choice of dose calculation algorithm on PTV and OAR doses in lung SBRT

Keynote webinar | Spotlight on antibody–drug conjugates in cancer